Sanofi Consumer Healthcare India profitability ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Dec 2025	FY25Dec 2024

Returns
	73.1%	73.1%	66.3%
	49.1%	49.1%	42.0%
	82.7%	82.7%	88.5%
	2,884.9%	2,422.3%	—
Margins
	37.8%	35.2%	37.4%
	33.9%	33.9%	36.7%
	—	20.3%	—
	38.4%	36.5%	34.1%
	28.6%	27.3%	25.0%
	30.7%	30.7%	59.2%
Additional
	25.6%	25.0%	26.7%
	—	52.8%	0.0%
	73.1%	34.5%	66.3%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

SANOFICONR₹3,468.00

Sanofi Consumer Healthcare India Limited

· Pharma & Health

₹ CrorePeersPGHL SANOFI SENORES INNOVACAP MOREPENLAB IOLCP FDC ASTRAZENMcap ₹7,976 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY25 31/12/2024	FY26 31/12/2025	Last 12M 30/09/2026
Returns
Return on Common Equity	66.30	73.09	73.09
Return on Assets	41.97	49.09	49.09
Return on Capital Employed	88.49	82.66	82.66
Return on Invested Capital	—	2,422.35	2,884.89
Margins
EBITDA Margin	37.35	35.18	37.75
Operating Margin	36.73	33.85	33.85
Incremental Operating Margin	—	20.27	—
Pretax Margin	34.06	36.46	38.39
Net Income Margin	24.98	27.33	28.57
FCF Margin	59.23	30.71	30.71
Additional
Effective Tax Rate	26.66	25.04	25.57
Dvd Payout Ratio	0.00	52.77	—
Sustainable Growth Rate	66.30	34.52	73.09

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.